MedTrace Logo

Screening of Pulmonary Hypertension in Methamphetamine Abusers

NCT04019600 · Status: SUSPENDED · Type: OBSERVATIONAL · Enrollment: 200

Last updated 2021-08-10

No results posted yet for this study

Summary

Methamphetamine is misuse if classified as a "likely" risk factor for pulmonary arterial hypertension (PAH). Nevertheless the actual prevalence of and a screening strategy for PAH in methamphetamine users have not been established. In this study, the prevalence of PAH will be investigated and its independent risk factors among methamphetamine users will be identified.

Conditions

  • Methamphetamine Abuse
  • Pulmonary Hypertension

Interventions

OTHER

Echocardiography

Demographic data and health risk factors will be collected on day of screening, together with the above tests. Right heart catheterization will be separately arranged in patients with a high echocardiographic probability of PAH. For those with a low-intermediate echocardiographic probability, screening will be repeated within 1 year to ensure true negativity of the original scan.

Sponsors & Collaborators

  • The University of Hong Kong

    lead OTHER

Principal Investigators

  • Siu-Han JoJo Hai, MBBS · Cardiac Division, the University of Hong Kong

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-12-23
Primary Completion
2022-12-22
Completion
2022-12-22

Countries

  • Hong Kong

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04019600 on ClinicalTrials.gov